CNAT - Conatus Pharmaceuticals Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.54
+0.82 (+17.37%)
At close: 4:00PM EDT

5.58 +0.04 (0.72%)
After hours: 7:50PM EDT

Stock chart is not supported by your current browser
Previous Close4.72
Open4.75
Bid5.55 x 1800
Ask5.75 x 800
Day's Range4.75 - 5.59
52 Week Range3.22 - 7.95
Volume1,745,116
Avg. Volume443,475
Market Cap167.147M
Beta2.26
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateJul 31, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.83
Trade prices are not sourced from all markets
  • GlobeNewswire16 hours ago

    Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension

    Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an invitation-only symposium on portal hypertension for institutional investors and research analysts on Thursday, September 27, 2018, from 4:30 p.m. to 6:00 p.m. ET in New York. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, and Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, will address the clinical importance of portal hypertension.

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...

  • GlobeNewswire2 days ago

    Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences

    Conatus Pharmaceuticals Inc. (CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease (September 26-27 in New York), senior management will conduct a series of scheduled meetings with investment professionals. At the Roth Capital Partners Battle of the NASH Thrones Investor Conference (October 17 in New York), senior management will conduct a series of scheduled meetings with investment professionals and participate in a panel discussion on fibrotic, inflammatory and metabolic agents.

  • Who Owns Most Of Conatus Pharmaceuticals Inc (NASDAQ:CNAT)?
    Simply Wall St.3 days ago

    Who Owns Most Of Conatus Pharmaceuticals Inc (NASDAQ:CNAT)?

    Every investor in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to seeRead More...

  • Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock
    Zacks21 days ago

    Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock

    Conatus Pharmaceuticals (CNAT) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Conatus (CNAT) Up 36.2% Since Last Earnings Report: Can It Continue?
    Zacks21 days ago

    Conatus (CNAT) Up 36.2% Since Last Earnings Report: Can It Continue?

    Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GlobeNewswire23 days ago

    Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference

    Conatus Pharmaceuticals Inc. (CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it has been invited to present at the BioCentury 25th Annual NewsMakers in the Biotech Industry Conference on Friday, September 7, 2018, in New York. Steven Mento, Ph.D., President and Chief Executive Officer of Conatus, is scheduled to present a corporate overview and business update at 10:30 a.m. ET. Host BioCentury handpicks only 48 companies to present their stories to biotech sector institutional investors.

  • ACCESSWIRE29 days ago

    Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics

    NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CNAT earnings conference call or presentation 1-Aug-18 8:30pm GMT

    Q2 2018 Conatus Pharmaceuticals Inc Earnings Call

  • Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally
    Zacks2 months ago

    Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally

    Conatus (CNAT) incurs narrower-than-expected loss in Q2. Sales miss estimates.

  • Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Misses Revenue Estimates

    Conatus (CNAT) delivered earnings and revenue surprises of 25.00% and -3.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Conatus: 2Q Earnings Snapshot

    The San Diego-based company said it had a loss of 15 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss ...

  • GlobeNewswire2 months ago

    Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates

    SAN DIEGO, Aug. 01, 2018-- Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results ...

  • What's in the Cards for Conatus (CNAT) This Earnings Season?
    Zacks2 months ago

    What's in the Cards for Conatus (CNAT) This Earnings Season?

    On Conatus' (CNAT) second-quarter 2018 conference call, investor focus will remain on the company's progress with respect to its lead candidate, emricasan.

  • GlobeNewswire2 months ago

    Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results

    Conatus Pharmaceuticals Inc. (CNAT) today announced that it will report financial results for the second quarter ended June 30, 2018, after the market close on Wednesday, August 1, 2018. Conatus will host a conference call and audio webcast at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018, to discuss the financial results and provide a corporate update. A live and archived audio webcast of the call will also be available in the Investors section of the Conatus website at www.conatuspharma.com.

  • GlobeNewswire3 months ago

    Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis

    Conatus Pharmaceuticals Inc. (CNAT) today announced the publication1 of results from preclinical studies of its pan-caspase inhibitor emricasan, demonstrating improvements in portal hypertension (elevated blood pressure in the vein flowing into the liver) and survival in two bile duct ligation mouse models of induced secondary biliary cirrhosis. In the first of the two current mouse studies, designed to evaluate treatment effect, emricasan decreased fibrosis, reduced portal hypertension and improved survival in mice with cirrhosis induced by bile duct ligation. The reductions in portal hypertension exceeded amounts that could be explained by the decreased fibrosis alone, indicating potential treatment effects both inside and outside the liver.

  • NASH Space in Focus as Galmed (GLMD) Posts Positive Data
    Zacks3 months ago

    NASH Space in Focus as Galmed (GLMD) Posts Positive Data

    Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.

  • Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?
    Zacks4 months ago

    Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report?

    Conatus Pharmaceuticals (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates
    Zacks5 months ago

    Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates

    Conatus (CNAT) reports in-line loss in Q1 while revenues beat estimates. Moreover, the top line improves year over year.

  • Associated Press5 months ago

    Conatus: 1Q Earnings Snapshot

    The San Diego-based company said it had a loss of 17 cents per share. The results matched Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also for ...

  • Analysts’ Ratings for Amicus and Its Peers in April
    Market Realist5 months ago

    Analysts’ Ratings for Amicus and Its Peers in April

    Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.

  • What's in the Cards for Conatus (CNAT) This Earnings Season?
    Zacks5 months ago

    What's in the Cards for Conatus (CNAT) This Earnings Season?

    Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.